Fine L G, Schlondorff D, Trizna W, Gilbert R M, Bricker N S
J Clin Invest. 1978 Jun;61(6):1519-27. doi: 10.1172/JCI109072.
Resistance of the chronically diseased kidney to vasopressin has been proposed as a possible explanation for the urinary concentrating defect of uremia. The present studies examined the water permeability and adenylate cyclase responsiveness of isolated cortical collecting tubules (CCT) from remnant kidneys of uremic rabbits to vasopressin. In the absence of vasopressin the CCTs of both normal and uremic rabbits were impermeable to water. At the same osmotic gradient, addition of a supramaximal concentration of vasopressin to the peritubular bathing medium led to a significantly lower net water flux per unit length (and per unit luminal surface area) in uremic CCTs than in normal CCTs. Transepithelial osmotic water permeability coefficient, P(f), was 0.0232 +/-0.0043 cm/s in normal CCTs and 0.0059+/-0.001 cm/s in uremic CCTs (P < 0.001). The impaired vasopressin responsiveness of the uremic CCTs was observed whether normal or uremic serum was present in the bath. Basal adenylate cyclase activity per microgram protein was comparable in normal and uremic CCTs. Stimulation by NaF led to equivalent levels of activity in both, whereas vasopressin-stimulated activity was 50% lower in the uremic than in the normal CCTs (P < 0.025). The cyclic AMP analogue, 8-bromo cyclic AMP, produced an increase in the P(f) of normal CCTs closely comparable to that observed with vasopressin. In contrast, the P(f) of uremic CCTs was only minimally increased by this analogue and was not further stimulated by theophylline. These studies demonstrate an impaired responsiveness of the uremic CCT to vasopressin. This functional defect appears to be a result, at least in part, of a blunted responsiveness of adenylate cyclase to vasopressin. The data further suggest that an additional defect in the cellular response to vasopressin may exist, involving a step (or steps) subsequent to the formation of cyclic AMP.A unifying concept of the urinary concentrating defect of uremia is proposed which incorporates a number of hitherto unexplained observations on the concentrating and diluting functions of the diseased kidney.
慢性病变肾脏对血管加压素的抵抗被认为可能是尿毒症患者尿液浓缩功能缺陷的一个解释。本研究检测了尿毒症兔残余肾脏分离的皮质集合管(CCT)对血管加压素的水通透性和腺苷酸环化酶反应性。在无血管加压素时,正常和尿毒症兔的CCT对水均不通透。在相同的渗透梯度下,向肾小管周围浴液中加入超最大浓度的血管加压素后,尿毒症CCT单位长度(和单位管腔表面积)的净水通量显著低于正常CCT。正常CCT的跨上皮渗透水通透系数P(f)为0.0232±0.0043 cm/s,尿毒症CCT为0.0059±0.001 cm/s(P<0.001)。无论浴液中存在正常血清还是尿毒症血清,均观察到尿毒症CCT对血管加压素的反应性受损。正常和尿毒症CCT每微克蛋白的基础腺苷酸环化酶活性相当。氟化钠刺激导致两者活性水平相当,而血管加压素刺激的活性在尿毒症CCT中比正常CCT低50%(P<0.025)。环磷酸腺苷类似物8-溴环磷酸腺苷使正常CCT的P(f)增加,与血管加压素作用时相近。相反,该类似物仅使尿毒症CCT的P(f)略有增加,且茶碱不能进一步刺激其增加。这些研究表明尿毒症CCT对血管加压素的反应性受损。这种功能缺陷似乎至少部分是由于腺苷酸环化酶对血管加压素的反应性减弱所致。数据进一步提示,在血管加压素细胞反应中可能存在另一个缺陷,涉及环磷酸腺苷形成后的一个或多个步骤。本文提出了一个关于尿毒症患者尿液浓缩功能缺陷的统一概念,该概念纳入了一些迄今对病变肾脏浓缩和稀释功能无法解释的观察结果。